DEFC14A: Kent Lake Urges Quanterix Stockholders to Vote Against Proposed Merger with Akoya Biosciences

Kent Lake Partners, owning 7.7% of Quanterix, is soliciting proxies to vote against the proposed merger with Akoya Biosciences, believing it is not in the best interests of Quanterix stockholders.

Summary

• Kent Lake Partners LP, owning approximately 7.7% of Quanterix, is urging stockholders to vote against the proposed merger with Akoya Biosciences.
• The special meeting to vote on the merger is scheduled for May 13, 2025.
• Kent Lake believes the merger is a transfer of value from Quanterix stockholders to Akoya stockholders and introduces unnecessary risk.
• They argue the merger undervalues Quanterix and weakens its balance sheet.
• Kent Lake also raises concerns about undisclosed conflicts of interest among certain Quanterix board members and the fairness of the merger terms.
• They believe the projections and synergy targets used to justify the merger are unrealistic.
• Kent Lake is soliciting proxies to vote against the share issuance proposal and the adjournment proposal related to the merger.
• Kent Lake believes that a standalone Quanterix provides superior long-term value creation opportunities for stockholders.

Sentiment

Score: 2

Explanation: The document expresses a strongly negative sentiment towards the proposed merger, citing concerns about valuation, financial risk, conflicts of interest, and unrealistic projections. Kent Lake is actively campaigning against the merger, indicating a high level of disapproval.

Negatives

• Kent Lake believes the proposed merger with Akoya Biosciences will destroy value for Quanterix shareholders.
• The merger is expected to reduce Quanterix's net cash per share significantly.
• Kent Lake has unresolved deal-breaker concerns about Akoya's financial stability and R&D pipeline.
• Kent Lake alleges material undisclosed conflicts of interest among certain Quanterix board members.
• Kent Lake believes the merger is a bailout for Akoya, which is in financial distress.
• Kent Lake argues that the projections and synergy targets used to justify the merger are unrealistic.
• Kent Lake highlights that Quanterix's share price has dropped approximately 55% since the merger announcement.
• Kent Lake believes the Quanterix Transaction Committee authorized an unprecedented $30 million Bridge Financing Commitment to Akoya without stockholder approval, on preferential and significantly mispriced terms.

Risks

• The merger could weaken Quanterix's balance sheet and increase the likelihood of liquidity issues.
• The merger is predicated on projections that do not reflect recent NIH funding cuts.
• Unresolved concerns about Akoya's cash burn, debt, and R&D pipeline could expose Quanterix stockholders to financial losses.
• Failure to realize projected cost synergies could negatively impact Quanterix's share price.
• Akoya's management anticipates the Combined Company will experience some revenue dis-synergies as a result of the Merger indicating that the positive synergies Quanterixs management team projects may be offset by revenue dis-synergies.

Future Outlook

Kent Lake believes that a standalone Quanterix provides superior long-term value creation opportunities for stockholders and urges stockholders to vote against the merger to preserve the Company's clear and compelling path toward long-term value creation.

Management Comments

• Quanterix CEO, Dr. Toloue, responded that he believed the stock was trading down due to investor concern over the financial restatement announced.
• On the March 17th, 2025, conference call, analysts asked Dr. Toloue to address the Akoya valuation disparity implied by the Merger to which he replied, 'If we looked at a point-in-time valuation in our business and what we do, that would be fairly shortsighted we can't make decisions on 1-month or 2-month swings or value windows, otherwise, we'd be a trading company.'
• Dr. Toloue stated on the March 17, 2025 conference call, 'clearly, were in an NIH-pressured environment, and I think a majority of the pressure you see on Quanterix or other companies is exactly hey, tools are indexed to academia, and there tends to be -or it looks like some paralysis in the market on spending in academia cost optimization.'

Industry Context

The document highlights concerns about the impact of NIH funding cuts on the life sciences sector and how this affects the proposed merger. It also mentions increased competition from emerging competitors such as Lunaphores COMET platform.

Comparison to Industry Standards

• The document compares the EV/Revenue multiples of Quanterix and Akoya in the proposed merger, arguing that Akoya is receiving a premium valuation.
• It notes that Akoya's advisor, PWP, recommended that Akoya would need to raise an additional $75 million of common equity at a 20% discount to the current market price in order to fund the company in a stand-alone scenario.
• The document states that the convertible strike price on the note equates to $3.54 per Akoya share, representing a 162% premium compared to Akoyas share price of $1.35 per share as of April 1, 2025.
• The document states that the Quanterix note bears an interest rate of SOFR + 6.80%.

Stakeholder Impact

• The proposed merger could significantly impact Quanterix stockholders, potentially leading to value destruction and increased financial risk.
• The merger could also affect Akoya stockholders, who would receive Quanterix shares in exchange for their Akoya shares.
• The document raises concerns about the fairness of the merger terms and potential conflicts of interest among Quanterix board members.

Next Steps

• Quanterix stockholders need to vote on the share issuance proposal and the adjournment proposal at the Special Meeting on May 13, 2025.
• Kent Lake is urging stockholders to sign, date, and return the GOLD proxy card voting AGAINST the proposals.

Key Dates

Keywords

Quanterix, Akoya Biosciences, merger, proxy solicitation, Kent Lake Partners, share issuance, stockholders, valuation, financial risk, conflicts of interest